Atara Biotherapeutics (NASDAQ:ATRA) Given “Hold” Rating at Canaccord Genuity Group

Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “hold” rating reaffirmed by equities researchers at Canaccord Genuity Group in a report issued on Tuesday, MarketBeat reports. They currently have a $6.00 price target on the biotechnology company’s stock. Canaccord Genuity Group’s target price would suggest a potential upside of 20.94% from the stock’s current price.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Atara Biotherapeutics in a research note on Monday, December 29th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $6.00.

Atara Biotherapeutics Price Performance

NASDAQ ATRA traded down $0.92 during mid-day trading on Tuesday, reaching $4.96. The stock had a trading volume of 995,825 shares, compared to its average volume of 937,434. Atara Biotherapeutics has a 1 year low of $4.81 and a 1 year high of $19.15. The company has a fifty day moving average price of $15.03 and a 200 day moving average price of $13.24. The stock has a market cap of $35.77 million, a PE ratio of 2.28 and a beta of -0.41.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.51. Atara Biotherapeutics had a negative return on equity of 41.78% and a net margin of 15.40%.The business had revenue of $3.45 million during the quarter, compared to analyst estimates of $2.74 million. As a group, equities research analysts expect that Atara Biotherapeutics will post -10.39 earnings per share for the current year.

Insider Transactions at Atara Biotherapeutics

In other Atara Biotherapeutics news, CEO Anhco Nguyen sold 2,915 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $13.19, for a total value of $38,448.85. Following the completion of the sale, the chief executive officer owned 64,974 shares in the company, valued at approximately $857,007.06. This represents a 4.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders sold 6,523 shares of company stock valued at $86,038. Corporate insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On Atara Biotherapeutics

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Atara Biotherapeutics by 6.6% during the third quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock worth $2,915,000 after purchasing an additional 12,677 shares in the last quarter. Mackenzie Financial Corp boosted its stake in Atara Biotherapeutics by 183.5% in the 3rd quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock worth $914,000 after purchasing an additional 41,302 shares during the period. Geode Capital Management LLC boosted its stake in Atara Biotherapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock worth $464,000 after purchasing an additional 1,457 shares during the period. Marshall Wace LLP purchased a new stake in Atara Biotherapeutics during the 2nd quarter valued at approximately $327,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Atara Biotherapeutics during the second quarter valued at approximately $31,000. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.